Taiwan Liposome Company, Ltd. today announced that it will feature a poster presentation covering the complete dataset from its Phase I/II study of the company’s lead product candidate, TLC599, in patients with knee osteoarthritis at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR),
Taiwan Liposome Company Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology, and oncology, today announced that it will feature a poster presentation covering the complete dataset from its Phase I/II study of the company’s lead product candidate, TLC599, in patients with knee osteoarthritis at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR), taking place September 6-9 in Kaohsiung, Taiwan. The trial, which was completed in 2017, concluded that an intraarticular injection of TLC599, a proprietary BioSeizer™ formulation of dexamethasone sodium phosphate, was well tolerated in all subjects, and that a trend of pain and symptom relief was observed in both treatment groups in the 12-week follow-up period.
Details of the presentation are as follows:
Title: Safety, Tolerability, and Efficacy of a Sustained Release Formulation of Dexamethasone Sodium Phosphate (TLC599) in Patients with Knee Osteoarthritis
Poster board number: 69
Date: Sunday, September 9, 2018
Time: Poster available all day, with presenter 10:00am - 10:30am / 12:10pm - 1:30pm (CST)
Location: Kaohsiung Exhibition Centre, N2 Exhibition Hall
Presenter: Dr. Chien-Chih Lai
About TLC599
TLC599 is a BioSeizer sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis (OA) pain. OA is a joint disorder involving the degeneration of the articular cartilage that leads to inflammation of the soft tissue and bony structures of the joint. Current intraarticular sustained release anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins called proteoglycans, resulting in chondrotoxicity. An in vivo toxicity study by proteoglycan staining of the cartilage showed TLC599 to be cartilage sparing compared to the current treatment. Data from its Phase I/II clinical trial demonstrated that a single dose of TLC599 at 6mg or 12 mg DSP led to rapid improvements in visual analog scale (VAS) pain scores and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Decreases in VAS and WOMAC were observed at one week post-injection and persisted without notable loss of effect through the end of the trial at 12 weeks. Phase II clinical trial extended the evaluation period to 24-weeks to better establish duration of efficacy.
(Contact for TLC)：
齊映筑 (Dawn Chi)
Tel: +886 2 2655 7377 # 136
Fax: +886 2 2655 7366
Email: dawn@tlcbio.com
This e-mail, and any attachments thereto, contain information that is not in the public domain, and is considered by Taiwan Liposome Company, Ltd. to be confidential and proprietary. This e-mail and any attachments are expected to be read and/or used only by the individual(s) for whom it is intended. If you have received it in error, please notify the sender by replying e-mail and immediately delete this e-mail and any attachments from your system immediately, without copying, reviewing, disclosing or re-transmitting or otherwise using them for any purpose. Thank you very much for your cooperation!
